Joint Commission proposes requirements for new stroke certification

A new optional certification is being developed by the Joint Commission for hospitals which “have the capability of providing high-quality endovascular thrombectomy for patients with ischemic stroke.”

The program, known as the Thrombectomy-capable Stroke Center Advanced Certification, now has proposed requirements from the Joint Commission and they’re seeking input from the field before finalizing them.

Requirements are built off typical program management standards with additions specific to Thrombectomy-capable Stroke Center Certification, such as:

·         Having the capacity to perform mechanical thrombectomy for the treatment of ischemic stroke 24 hours a day, 7 days a week

·         Being able to perform Catheter angiography, Computed tomography (CT) of the head, Computed tomography angiography (CTA), MRI, and Magnetic resonance angiography (MRA) 24 hours a day, 7 days a week

·         Having a transfer agreement with at least one comprehensive stroke center

·         Protocols and care paths (preprinted or electronic documents) are available in the emergency department, acute care areas, and stroke unit for the acute assessment and treatment of patients with ischemic or hemorrhagic stroke

The full list of proposed requirements can be read here.

Comments on the certification standards will be accepted online or by mail through May 29. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.